<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720108</url>
  </required_header>
  <id_info>
    <org_study_id>EPCATII.001</org_study_id>
    <nct_id>NCT01720108</nct_id>
  </id_info>
  <brief_title>Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty</brief_title>
  <acronym>EPCAT II</acronym>
  <official_title>Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators want to look at whether using aspirin instead of rivaroxaban
      (after initial treatment with rivaroxaban) works as well at preventing blood clots while also
      reducing risk of bleeding and is more cost effective in patients who have either a total hip
      replacement or total knee replacement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptomatic venous thromboembolism</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>major or clinically relevant non-major bleeding</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound infection</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3426</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban and ASA</intervention_name>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_label>ASA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. All patients undergoing elective total hip or knee arthroplasty at the participating
        institutions will be potentially eligible for this study

        Exclusion Criteria:

          1. Hip or lower limb fracture in the previous three months

          2. Metastatic cancer

          3. Life expectancy less than 6 months

          4. History of major bleeding that in the judgment of the investigator precludes use of
             anticoagulant prophylaxis

          5. History of aspirin allergy, active peptic ulcer disease or gastritis that in judgment
             of investigator precludes use of aspirin

          6. History of significant hepatic disease or any other condition that in the judgement of
             the investigator precludes the use of rivaroxaban

          7. Creatinine clearance less than 30 ml per minute

          8. Platelet count less than 100 x 109 /L

          9. Need for long-term anticoagulation due to a preexisting co-morbid condition or due to
             the development of venous thromboembolism following surgery but prior to randomization

         10. Did not or will not receive rivaroxaban post-operatively for VTE prophylaxis

         11. Bilateral total hip arthroplasty or simultaneous hip and knee arthroplasty

         12. Major surgical procedure within the previous three months

         13. Requirement for major surgery post arthroplasty within 90 day period

         14. Chronic daily aspirin use with dose greater than 100 mg a day

         15. Women of child bearing potential who are not abstinent or do not use appropriate
             contraception throughout the study drug period

         16. Geographical inaccessibility for follow-up

         17. Unwilling or unable to give consent

         18. Previous participation in the study

         19. Concomitant use with drugs that are strong inhibitors or inducers of both P-gp and
             CYP3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2012</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>David Anderson</investigator_full_name>
    <investigator_title>Head, Department of Medicine, CDHA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

